US Patent

US9326945 — Apixaban formulations

Formulation · Assigned to Bristol Myers Squibb Co · Expires 2031-02-24 · 5y remaining

Vulnerability score 61/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects formulations of apixaban, specifically crystalline apixaban particles with a certain size, used for treating and preventing blood clots.

USPTO Abstract

Compositions comprising crystalline apixaban particles having a D 90 equal to or less than 89 Î¼m, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to for the treatment and/or prophylaxis of thromboembolic disorders.

Drugs covered by this patent

Eliquis (apixaban) · Bristol-Myers Squibb

Patent Metadata

Patent number: US9326945
Jurisdiction: US
Classification: Formulation
Expires: 2031-02-24
Drug substance claim: No
Drug product claim: Yes
Assignee: Bristol Myers Squibb Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.